Lantheus Holdings (LNTH) Asset Writedowns and Impairment (2013 - 2026)
Lantheus Holdings (LNTH) reported Asset Writedowns and Impairment of $1.5 million for Q1 2026, up 211.54% year-over-year from $493358.0 in Q1 2025, and up 153.57% quarter-over-quarter from -$2.9 million in Q4 2025.
Lantheus Holdings (LNTH) Asset Writedowns and Impairment (2013 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has 14 years of Asset Writedowns and Impairment data on file, last reported at $1.5 million in Q1 2026.
- Asset Writedowns and Impairment for Q1 2026 came in at $1.5 million, up 211.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 million (up 157.85% YoY), and the FY2024 annual result was -$904000.0, down 111.42% from the prior year.
- Asset Writedowns and Impairment grew to $1.5 million in Q1 2026 per LNTH's latest filing, from -$2.9 million in the prior quarter.
- Over five years, Asset Writedowns and Impairment peaked at $132.1 million in Q1 2023 and troughed at -$130.1 million in Q4 2023.
- A 5-year average of $1.2 million and a median of $1.5 million in 2026 frame the typical range for Asset Writedowns and Impairment.
- The sharpest annual moves came in 2023 and 2025: Asset Writedowns and Impairment slumped 1921.36% in 2023, then surged 378.12% in 2025.
- A 5-year view of Asset Writedowns and Impairment shows it stood at $7.1 million in 2022, then tumbled by 1921.36% to -$130.1 million in 2023, then jumped by 98.74% to -$1.6 million in 2024, then plunged by 74.73% to -$2.9 million in 2025, then jumped by 153.57% to $1.5 million in 2026.
- Business Quant data shows LNTH's Asset Writedowns and Impairment at $1.5 million in Q1 2026, -$2.9 million in Q4 2025, and $1.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.54 Mn |
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | -2.87 Mn |
| Dec 31, 2025 | -2.87 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.31 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Dec 31, 2024 | -1.64 Mn |
| Dec 31, 2024 | -1.64 Mn |
| Sep 30, 2024 | -1.19 Mn |
| Sep 30, 2024 | -1.19 Mn |
| Jun 30, 2024 | -832,000.00 |
| Jun 30, 2024 | -832,000.00 |
| Mar 31, 2024 | 2.76 Mn |
| Mar 31, 2024 | 2.76 Mn |
| Dec 31, 2023 | -130.14 Mn |
| Dec 31, 2023 | -130.14 Mn |